Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hapten – hapten-carrier complex – or...
Reexamination Certificate
2007-09-04
2007-09-04
Kemmerer, Elizabeth (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hapten, hapten-carrier complex, or...
C530S300000, C530S324000, C530S326000
Reexamination Certificate
active
10716981
ABSTRACT:
The purified nerve growth factor consisting of 116 amino acids from the venom of Naja kaouthia snake was fragmented by trypsin digestion. The fragments were isolated individually by high pressure liquid chromatography (HPLC). Thus separated fragments were tested for the biological activity of neurite growth on rat adrenal pheochromocytoma (PC12) cells. The fragment which showed the most activity was named ADESH. Subsequently, ADESH was sequenced. Synthetic ADESH was constructed using ten amino acids N L G E H P V C D S (SEQ. ID. NO: 3) of the fragment from its N-terminal is designated as AD-10. Different versions of synthetic ADESH such as AD-15 and AD-5 consisting of 15 and 5 amino acids respectively were constructed; having the sequence: N L G E H P V C D S T D T W V (SEQ. ID. NO: 2) for AD-15 and N L G E H (SEQ. ID. NO: 4) for AD-5. The synthetic AD-15 and AD-5 mimic the biological activity of the natural NGF.
REFERENCES:
patent: 5814603 (1998-09-01), Oldenburg et al.
patent: 6984486 (2006-01-01), Schubert et al.
patent: 19508672 (1996-09-01), None
Inoue et al. FEBS Lett. 1991; 279: 38-40.
Haller, MF et al “Nerve Growth Factor Delivery Systems” Journal of Controlled Release vol. 53, 1-6 (1998).
Dicou, Eleni et al “Two Peptides Derived from the nerve Growth Factor Precursor are Biologically Active” J of Cell Biol, vol. 136, No. 2, 389-390 (Jan. 27, 1997).
Beglova et al : “Solution structure . . . of a bioactive peptide . . . ” J of Biol. Chem., vol. 273, No. 37., Sep. 11, 1998 pp. 23652-23658.
Longo et al: “Synthetic NGF Peptide . . . ” J of Neurosci Res, Wiley Liss, vol. 48, Apr. 1, 1997, pp. 1-17.
Estenne-Bouhtou et al: “Design, synthesis, . . . of NGF Mimetics” Int. J of Peptide and Protein Res., Munksgaard, Copenhagen, DK vol. 48, No. 4, Oct. 1, 1996, pp. 337-346.
Lipps Binie V.
Lipps Frederick W.
Borgeest Christina
Casperson John R
Kemmerer Elizabeth
LandOfFree
Synthetic peptide for neurological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic peptide for neurological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptide for neurological disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3802293